Derma Sciences, Inc. (DSCI) Begins Screening Patients in Second Phase 3 Trial With DSC127 for Healing Diabetic Foot Ulcers
4/26/2013 10:12:16 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that patient screening has begun in the second of two Phase 3 clinical trials with the investigational topical drug candidate DSC127 for the treatment of diabetic foot ulcers. This second trial will have three arms of 211 patients each, and is evaluating a 0.03% formulation of DSC127 against a topical vehicle and against a standard of care hydrogel. The first Phase 3 trial, which commenced in February with two arms of 211 patients each, is evaluating the 0.03% formulation of DSC127 against a topical vehicle.
Help employers find you! Check out all the jobs and post your resume.
comments powered by